抗炎症治療薬の世界市場 - 成長、将来展望、競合分析（2022年～2030年）

世界の抗炎症治療薬の市場規模は、2030年までに1,861億米ドルに達し、2022年から2030年までの予測期間中にCAGRで8.5%の成長が予測されています。生物製剤と免疫選択的抗炎症誘導体（ImSAID）は、市場で主要な役割を果たす有望な薬剤クラスです。世界の抗炎症治療薬市場では、主要企業が北米に本社を置くため、北米が明らかに大きなシェアを占めています。呼吸器疾患や自己免疫疾患の発生率の上昇、アジア太平洋と欧州での投資の拡大、拡張パイプラインにおける相当数の生物製剤が、世界の抗炎症治療薬の市場の発展を推進しています。

当レポートでは、世界の抗炎症治療薬市場について調査し、市場動向、競合情報、セグメント分析、新興動向、技術分析、企業プロファイルなどの情報を提供しています。

目次

第1章 序文

• レポートの説明
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 市場スナップショット：世界の抗炎症治療薬市場
• 世界の抗炎症治療薬市場：薬剤別（2021年）
• 世界の抗炎症治療薬市場：適応症別（2021年）
• 世界の抗炎症治療薬市場：地域別（2021年）
• COVID-19の影響
• 魅力的な投資提案：地域別（2021年）
• 競合分析
  • 主要な抗炎症治療薬市場ベンダーの市場ポジショニング
  • 抗炎症治療薬市場ベンダーが採用する戦略
  • 主要な業界戦略
  • ティア分析2021年対2030年
• 主な購入基準
• 主な事例報告
• シナリオ分析
• 市場プロファイリング
• 販売・マーケティング計画
• 主要市場の結論
• 戦略的提言

第3章 抗炎症治療薬市場：ビジネスの見通しと市場力学

• イントロダクション
• 世界の抗炎症治療薬市場金額（2020年～2030年）
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進要因・抑制要因の影響分析
• シーソー分析
• ポーターのファイブフォースモデル
• PESTEL分析
• ヘプタリシス分析
• 5つの根本原因分析と関連ソリューションによるビジネス上の問題の重要な調査

第4章 抗炎症治療薬市場：薬剤別（2020年～2030年）

• 市場概要
• 成長と収益分析：2021年対2030年
• 市場セグメンテーション
  • 非ステロイド性抗炎症薬（NSAID）
  • コルチコステロイド
  • 生物製剤
  • 免疫選択的抗炎症誘導体（ImSAID）

第5章 抗炎症治療薬市場：適応症別（2020年～2030年）

• 市場概要
• 成長と収益分析：2021年対2030年
• 市場セグメンテーション
  • 関節リウマチ
  • 慢性閉塞性肺疾患（COPD）
  • 多発性硬化症
  • 炎症性腸疾患（IBD）
  • 乾癬性関節炎
  • 痛風
  • その他（変形性関節症、全身性狼瘡、乾癬）

第6章 北米の抗炎症治療薬市場（2020年～2030年）

• 市場概要
• 抗炎症治療薬市場：薬剤別（2020年～2030年）
• 抗炎症治療薬市場：適応症別（2020年～2030年）
• 抗炎症治療薬市場：地域別（2020年～2030年）
  • 北米

第7章 英国・欧州連合の抗炎症治療薬市場（2020年～2030年）

• 市場概要
• 抗炎症治療薬市場：薬剤別（2020年～2030年）
• 抗炎症治療薬市場：適応症別（2020年～2030年）
• 抗炎症治療薬市場：地域別（2020年～2030年）
  • 英国・欧州連合

第8章 アジア太平洋の抗炎症治療薬市場（2020年～2030年）

• 市場概要
• 抗炎症治療薬市場：薬剤別（2020年～2030年）
• 抗炎症治療薬市場：適応症別（2020年～2030年）
• 抗炎症治療薬市場：地域別（2020年～2030年）
  • アジア太平洋

第9章 ラテンアメリカの抗炎症治療薬市場（2020年～2030年）

• 市場概要
• 抗炎症治療薬市場：薬剤別（2020年～2030年）
• 抗炎症治療薬市場：適応症別（2020年～2030年）
• 抗炎症治療薬市場：地域別（2020年～2030年）
  • ラテンアメリカ

第10章 中東・アフリカの抗炎症治療薬市場（2020年～2030年）

• 市場概要
• 抗炎症治療薬市場：薬剤別（2020年～2030年）
• 抗炎症治療薬市場：適応症別（2020年～2030年）
• 抗炎症治療薬市場：地域別（2020年～2030年）
  • 中東・アフリカ

第11章 企業プロファイル

• Pfizer, Inc.
• Amgen, Inc.
• AstraZeneca plc
• Eli Lily and Company
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Company, Inc.
• Novartis International AG
• AbbVie Inc
• F. Hoffmann-La Roche AG

List of Tables

• TABLE 1 Global Anti-Inflammatory Therapeutics Market By Drug, 2020-2030, USD (Million)
• TABLE 2 Global Anti-Inflammatory Therapeutics Market By Indication, 2020-2030, USD (Million)
• TABLE 3 North America Anti-Inflammatory Therapeutics Market By Drug, 2020-2030, USD (Million)
• TABLE 4 North America Anti-Inflammatory Therapeutics Market By Indication, 2020-2030, USD (Million)
• TABLE 5 UK and European Union Anti-Inflammatory Therapeutics Market By Drug, 2020-2030, USD (Million)
• TABLE 6 UK and European Union Anti-Inflammatory Therapeutics Market By Indication, 2020-2030, USD (Million)
• TABLE 7 Asia Pacific Anti-Inflammatory Therapeutics Market By Drug, 2020-2030, USD (Million)
• TABLE 8 Asia Pacific Anti-Inflammatory Therapeutics Market By Indication, 2020-2030, USD (Million)
• TABLE 9 Latin America Anti-Inflammatory Therapeutics Market By Drug, 2020-2030, USD (Million)
• TABLE 10 Latin America Anti-Inflammatory Therapeutics Market By Indication, 2020-2030, USD (Million)
• TABLE 11 Middle East and Africa Anti-Inflammatory Therapeutics Market By Drug, 2020-2030, USD (Million)
• TABLE 12 Middle East and Africa Anti-Inflammatory Therapeutics Market By Indication, 2020-2030, USD (Million)

List of Figures

• FIG. 1 Global Anti-Inflammatory Therapeutics Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Anti-Inflammatory Therapeutics Market: Quality Assurance
• FIG. 5 Global Anti-Inflammatory Therapeutics Market, By Drug, 2021
• FIG. 6 Global Anti-Inflammatory Therapeutics Market, By Indication, 2021
• FIG. 7 Global Anti-Inflammatory Therapeutics Market, By Geography, 2021
• FIG. 8 Global Anti-Inflammatory Therapeutics Market, By Drug, 2021 Vs 2030, %
• FIG. 9 Global Anti-Inflammatory Therapeutics Market, By Indication, 2021 Vs 2030, %
• FIG. 10 U.S. Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 11 Canada Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 12 Rest of North America Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 13 UK Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 14 Germany Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 15 Spain Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 16 Italy Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 17 France Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 18 Rest of Europe Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 19 China Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 20 Japan Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 21 India Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 22 Australia Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 23 South Korea Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 24 Rest of Asia Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 25 Brazil Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 26 Mexico Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 27 Rest of Latin America Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 28 GCC Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 29 Africa Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030
• FIG. 30 Rest of Middle East and Africa Anti-Inflammatory Therapeutics Market (US$ Million), 2020 - 2030

Industry Outlook

Anti-inflammatory therapeutics market expected to reach by US$ 186.1 Bn by 2030 with CAGR of 8.5% during the forecast period from 2022 to 2030. Biologics and immune selective anti-inflammatory derivatives (ImSAIDs) are the promising drugs classes playing major role in the market. North America clearly holds major share in the global anti-inflammatory therapeutics market, as the key companies headquartered in the region. Non-steroidal anti-inflammatory drugs are used for the treatment of chronic and acute pain. Either its headache or migraines, ligament sprain, menstrual pain, and rheumatoid arthritis, anti-inflammatory drugs can treat faster as compared to other drugs. They are equipped for bringing down the level of prostaglandins, the chemicals are responsible for reducing pain, swelling, and inflammation.

Rising incidence of respiratory and autoimmune diseases, expanding investments in Asia-Pacific and Europe and a substantial number of biologics in the expansion pipeline will drive the development of global anti-inflammatory therapeutics market. Factors such as, the presence of recognized markets for biologics and corticosteroids, larger acceptance of OTC NSAIDs, for example, naproxen and ibuprofen, in countries like Indian and China would additionally enhance the market growth in Asia Pacific region.

The United States is leading market in North America at the global level, and Japan is the foremost market for biologic drugs in Asia Pacific market. While United Kingdom is projected to lead the market in Europe. Moreover, in Japan, the administration is currently focusing on the establishment of viable generic drugs. Furthermore, China anticipated to rise as the new market front-runner in Asia Pacific market by 2026 owing to rapidly developing economy, developing healthcare facilities and immense patient base. In India, the introduction of biosimilars and continuously improving healthcare expenses will be the main variables encouraging the development of anti-inflammatory therapeutics market.

"Corticosteroids drugs boosting the growth of anti-inflammatory therapeutics market"

Currently, corticosteroids are the largest drug type by value and estimated to retain its prominence and biologics to record highest double-digit CAGR throughout the forecast period from 2022-2030. According to WHO the prevalence of rheumatoid arthritis contrasts between 0.3% and 1% which is more typical in women. About 1.5 million people in the United States have rheumatoid arthritis (RA). Corticosteroids are used to treat systemic lupus, severe psoriasis and to suppress the immune system.

"IBD segment by indication to record highest double digit CAGR during the forecast period"

According to CDC (Centers for Disease Control and Prevention), in the US, it is presently projected that around 1 Mn to1.3 Mn people affected by IBD. Moreover, studies from various nations exhibit that the incidence of IBD is growing, particularly in adolescence. Right now, the most elevated yearly incidence of IBD (Inflammatory bowel disease) in Europe was 12.7 for every 100,000 person-years for CD (Crohn's Disease) and 24.3 for every 100,000 person-years for UC (Ulcerative Colitis). In North America, the yearly incidence of IBD was 19.2 for every 100,000 men a long time for UC and 20.2 for every 100,000 person-years for the CD. Whereas in Asia and the Middle East it was 6.3 for every 100,000 person-years for UC and 5.0 for every 100,000 person-years for the CD. The maximum prevalence for UC was 505 for every 100,000 people in Europe and 249 for every 100,000 people in North America. The yearly prevalence of CD was 322 for every 100,000 people in Europe and 319 for every 100,000 people in North America. So, it is expected that these factors will encourage the development of anti-inflammatory therapeutics market.

This detailed study further defines the major qualitative market assessment factors including main market driver, market trends and restraints, to help in better understanding of global anti-inflammatory therapeutics market. Each market valuation factor comprising challenges, market drivers and opportunities are widely elucidated considering the existing market scenario. This report graphically maps the market players based on their market initiatives and product offering, strategies and business strength. Moreover, the report provides attractive investment proposition based on the extensive geographical research. Key players profiled in the report include: AbbVie Inc., Amgen Inc., AstraZeneca plc, Eli Lily and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Company, Inc., Novartis International AG, Pfizer Inc., and F. Hoffmann-La Roche AG among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anti-Inflammatory Therapeutics market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Anti-Inflammatory Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Corticosteroids

Biologics

Immune Selective Anti-inflammatory Derivatives (ImSAIDs)

Indication

Rheumatoid Arthritis

Chronic obstructive pulmonary disease (COPD)

Multiple Sclerosis

Inflammatory bowel disease (IBD)

Psoriatic Arthritis

Gout

Others (Osteoarthritis, Systemic lupus, Psoriasis)

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Anti-Inflammatory Therapeutics market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Anti-Inflammatory Therapeutics market?

Which is the largest regional market for Anti-Inflammatory Therapeutics market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Anti-Inflammatory Therapeutics market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Anti-Inflammatory Therapeutics market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Anti-Inflammatory Therapeutics Market
• 2.2. Global Anti-Inflammatory Therapeutics Market, By Drug, 2021 (US$ Million)
• 2.3. Global Anti-Inflammatory Therapeutics Market, By Indication, 2021 (US$ Million)
• 2.4. Global Anti-Inflammatory Therapeutics Market, By Geography, 2021 (US$ Million)
• 2.5. Impact of Covid 19
• 2.6. Attractive Investment Proposition by Geography, 2021
• 2.7. Competitive Analysis
  • 2.7.1. Market Positioning of Key Anti-Inflammatory Therapeutics Market Vendors
  • 2.7.2. Strategies Adopted by Anti-Inflammatory Therapeutics Market Vendors
  • 2.7.3. Key Industry Strategies
  • 2.7.4. Tier Analysis 2021 Versus 2030
• 2.8. Key Buying Criteria
• 2.9. Key Case Reports
• 2.10. Scenario Analysis
  • 2.10.1. Optimistic estimates and analysis
  • 2.10.2. Realistic estimates and analysis
  • 2.10.3. Pessimistic estimates and analysis
• 2.11. Market Profiling
• 2.12. Sales and Marketing Plan
• 2.13. Top Market Conclusions
• 2.14. Strategic Recommendations

3. Anti-Inflammatory Therapeutics Market: Business Outlook & Market Dynamics

• 3.1. Introduction
• 3.2. Global Anti-Inflammatory Therapeutics Market Value, 2020 - 2030, (US$ Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers
  • 3.3.2. Market Restraints
  • 3.3.3. Key Challenges
  • 3.3.4. Key Opportunities
• 3.4. Impact Analysis of Drivers and Restraints
• 3.5. See-Saw Analysis
• 3.6. Porter's Five Force Model
  • 3.6.1. Supplier Power
  • 3.6.2. Buyer Power
  • 3.6.3. Threat Of Substitutes
  • 3.6.4. Threat Of New Entrants
  • 3.6.5. Competitive Rivalry
• 3.7. PESTEL Analysis
  • 3.7.1. Political Landscape
  • 3.7.2. Economic Landscape
  • 3.7.3. Technology Landscape
  • 3.7.4. Legal Landscape
  • 3.7.5. Social Landscape
• 3.8. Heptalysis Analysis
• 3.9. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions

4. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)

• 4.1. Market Overview
• 4.2. Growth & Revenue Analysis: 2021 Versus 2030
• 4.3. Market Segmentation
  • 4.3.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 4.3.2. Corticosteroids
  • 4.3.3. Biologics
  • 4.3.4. Immune Selective Anti-inflammatory Derivatives (ImSAIDs)

5. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2021 Versus 2030
• 5.3. Market Segmentation
  • 5.3.1. Rheumatoid Arthritis
  • 5.3.2. Chronic obstructive pulmonary disease (COPD)
  • 5.3.3. Multiple Sclerosis
  • 5.3.4. Inflammatory bowel disease (IBD)
  • 5.3.5. Psoriatic Arthritis
  • 5.3.6. Gout
  • 5.3.7. Others (Osteoarthritis, Systemic lupus, Psoriasis)

6. North America Anti-Inflammatory Therapeutics Market, 2020-2030, USD (Million)

• 6.1. Market Overview
• 6.2. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
• 6.3. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
• 6.4.Anti-Inflammatory Therapeutics Market: By Region, 2020-2030, USD (Million)
  • 6.4.1.North America
    • 6.4.1.1. U.S.
      • 6.4.1.1.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 6.4.1.1.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 6.4.1.2. Canada
      • 6.4.1.2.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 6.4.1.2.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 6.4.1.3. Rest of North America
      • 6.4.1.3.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 6.4.1.3.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)

7. UK and European Union Anti-Inflammatory Therapeutics Market, 2020-2030, USD (Million)

• 7.1. Market Overview
• 7.2. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
• 7.3. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
• 7.4.Anti-Inflammatory Therapeutics Market: By Region, 2020-2030, USD (Million)
  • 7.4.1.UK and European Union
    • 7.4.1.1. UK
      • 7.4.1.1.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.4.1.1.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 7.4.1.2. Germany
      • 7.4.1.2.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.4.1.2.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 7.4.1.3. Spain
      • 7.4.1.3.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.4.1.3.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 7.4.1.4. Italy
      • 7.4.1.4.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.4.1.4.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 7.4.1.5. France
      • 7.4.1.5.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.4.1.5.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 7.4.1.6. Rest of Europe
      • 7.4.1.6.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.4.1.6.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)

8. Asia Pacific Anti-Inflammatory Therapeutics Market, 2020-2030, USD (Million)

• 8.1. Market Overview
• 8.2. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
• 8.3. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
• 8.4.Anti-Inflammatory Therapeutics Market: By Region, 2020-2030, USD (Million)
  • 8.4.1.Asia Pacific
    • 8.4.1.1. China
      • 8.4.1.1.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.1.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 8.4.1.2. Japan
      • 8.4.1.2.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.2.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 8.4.1.3. India
      • 8.4.1.3.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.3.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 8.4.1.4. Australia
      • 8.4.1.4.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.4.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 8.4.1.5. South Korea
      • 8.4.1.5.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.5.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 8.4.1.6. Rest of Asia Pacific
      • 8.4.1.6.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.4.1.6.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)

9. Latin America Anti-Inflammatory Therapeutics Market, 2020-2030, USD (Million)

• 9.1. Market Overview
• 9.2. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
• 9.3. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
• 9.4.Anti-Inflammatory Therapeutics Market: By Region, 2020-2030, USD (Million)
  • 9.4.1.Latin America
    • 9.4.1.1. Brazil
      • 9.4.1.1.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 9.4.1.1.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 9.4.1.2. Mexico
      • 9.4.1.2.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 9.4.1.2.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 9.4.1.3. Rest of Latin America
      • 9.4.1.3.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 9.4.1.3.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)

10. Middle East and Africa Anti-Inflammatory Therapeutics Market, 2020-2030, USD (Million)

• 10.1. Market Overview
• 10.2. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
• 10.3. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
• 10.4.Anti-Inflammatory Therapeutics Market: By Region, 2020-2030, USD (Million)
  • 10.4.1.Middle East and Africa
    • 10.4.1.1. GCC
      • 10.4.1.1.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 10.4.1.1.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 10.4.1.2. Africa
      • 10.4.1.2.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 10.4.1.2.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)
    • 10.4.1.3. Rest of Middle East and Africa
      • 10.4.1.3.1. Anti-Inflammatory Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 10.4.1.3.2. Anti-Inflammatory Therapeutics Market: By Indication, 2020-2030, USD (Million)

11. Company Profile

• 11.1. Pfizer, Inc.
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Portfolio
  • 11.1.4. Strategic Initiatives
• 11.2. Amgen, Inc.
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Portfolio
  • 11.2.4. Strategic Initiatives
• 11.3. AstraZeneca plc
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Portfolio
  • 11.3.4. Strategic Initiatives
• 11.4. Eli Lily and Company
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Portfolio
  • 11.4.4. Strategic Initiatives
• 11.5. GlaxoSmithKline plc
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Portfolio
  • 11.5.4. Strategic Initiatives
• 11.6. Johnson & Johnson
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Portfolio
  • 11.6.4. Strategic Initiatives
• 11.7. Merck & Company, Inc.
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Portfolio
  • 11.7.4. Strategic Initiatives
• 11.8. Novartis International AG
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Portfolio
  • 11.8.4. Strategic Initiatives
• 11.9. AbbVie Inc
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Portfolio
  • 11.9.4. Strategic Initiatives
• 11.10. F. Hoffmann-La Roche AG
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Portfolio
  • 11.10.4. Strategic Initiatives